Combination therapies of multiple ICS strategies involving OX40-engagement (i.e., ivuxolimab with utolimumab and GSK3174998 with GSK1795091) do show anti-tumour immune reactivity. This evidence concerns the gene TNFRSF4 and neoplasm.